NEW YORK, NY / ACCESSWIRE / March 27, 2020 / Dundee Corp. (OTCMKTS:DDEJF) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 27, 2020 at 10:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60907

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582790

NEW YORK, NY / ACCESSWIRE / March 27, 2020 / Gafisa SA (OTCMKTS:GFASY) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 27, 2020 at 10:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60631

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582789

A C200 Microturbine will Form the Backbone of the Combined Heat and Power Project

VAN NUYS, CA / ACCESSWIRE / March 27, 2020 / Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it has partnered with the New York Power Authority (NYPA) and Brenmiller Energy on a groundbreaking thermal energy storage project for Purchase College, State University of New York (SUNY). The project received a one million dollar grant from the Israel-United States Binational Industrial Research and Development (BIRD) Foundation to investigate low emission thermal energy storage as a means to increase the efficiency of standard combined heat and power (CHP) systems.

Capstone Microturbine Driving a Brenmiller bGen Energy Zero Carbon Thermal Storage Unit

The installation will serve as a demonstration project for innovative thermal energy storage technology in New York. The collaboration is one of many projects deployed as part of New York State's Energy Storage Roadmap that includes energy storage targets of 1,500 megawatts by 2025-the equivalent electricity demand of one-fifth of all New York homes.

"Our microturbine will directly pipe low emission exhaust gas into a Brenmiller bGen zero carbon thermal storage unit so that it can extract and store the heat until it is needed. The system represents an alternative to battery storage with potentially greater discharge durations," said Darren Jamison, Capstone Turbine President and Chief Executive Officer. "This new groundbreaking thermal energy storage unit is designed to shift large amounts of energy over long periods of time, thereby providing an effective solution over other technologies when grid-scale energy storage of long duration is required," added Jamison.

RSP Systems, Capstone's exclusive distributor in New York and Connecticut (www.rsp-systems.com), secured the order for the C200R microturbine that will be utilized in a CHP application. The innovative cogeneration system will be installed to support the College's physical education building, displacing the aging district heating loop in the central heating plant and providing baseload electricity, which is projected to save the State University of New York about $100,000 per year while reducing the facility's carbon footprint.

RSP Systems is proud to have been selected as the prime mover for the cogeneration and thermal storage project at SUNY Purchase. Thermal storage improves a CHP system's efficiency and effectiveness while enhancing its sustainable performance and hardens a facility," said Cory Glick, President of RSP Systems. "In addition, this project is an example of our shift to provide CHP-based hybrid solutions for our clients that can also benefit from adding battery storage, solar energy, and new technologies into their green energy and back-up power solution toolbox," concluded Mr. Glick.

About Capstone Turbine Corporation

Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup, providing scalable systems focusing on 30 kWs to 10 MWs that operate on a variety of gaseous or liquid fuels and are the ideal solution for today's distributed power generation needs. To date, Capstone has shipped over 9,000 units to 73 countries and in FY19, saved customers an estimated $253 million in annual energy costs and 350,000 tons of carbon.

For more information about the company, please visit www.capstoneturbine.com. Follow Capstone Turbine on Twitter, LinkedIn, Instagram, and YouTube.

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is used in the federal securities laws. Forward-looking statements may be identified by words such as "expects," "believes," "objective," "intend," "targeted," "plan" and similar phrases. These forward-looking statements are subject to numerous assumptions, risks and uncertainties described in Capstone's filings with the Securities and Exchange Commission that may cause Capstone's actual results to be materially different from any future results expressed or implied in such statements. Capstone cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Capstone undertakes no obligation, and specifically disclaims any obligation, to release any revisions to any forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

"Capstone" and "Capstone Microturbine" are registered trademarks of Capstone Turbine Corporation. All other trademarks mentioned are the property of their respective owners.

CONTACT:

Capstone Turbine Corporation
Investor and investment media inquiries:
818-407-3628
ir@capstoneturbine.com

Integra Investor Relations
Shawn M. Severson
415-226-7747
cpst@integra-ir.com

SOURCE: Capstone Turbine Corporation

ReleaseID: 582794

VANCOUVER, BC / ACCESSWIRE / March 27, 2020 / FIORE GOLD LTD. (TSXV:F)(OTCQB:FIOGF) ("Fiore" or the "Company") is announcing that in response to the ongoing global COVID-19 pandemic and consistent with the public health measures enacted and recommended by the Federal and Provincial Governments of Canada, it will host its annual general meeting of shareholders (the "AGM" or the "meeting") on a virtual, electronic basis only, at the same date and time as planned, 10:00 AM Eastern Time Tuesday, April 7, 2020. The Company has made this decision to proactively protect the health and wellbeing of its shareholders, employees and service partners that participate in the AGM.

The Company will not hold an in-person meeting at its Toronto office as previously communicated in the Notice of Annual General Meeting dated March 11, 2020 that was sent to shareholders and filed on SEDAR. Although for corporate law purposes under the Business Corporations Act (British Columbia), the physical location of the meeting will be considered to be Fiore's Toronto office, where the meeting would otherwise have been held. In order to streamline the virtual meeting process, the Company encourages shareholders to vote in advance of the meeting using the Voting Instruction Form or the Form of Proxy mailed to them with the meeting materials. Shareholders wishing to attend the AGM may continue to do so by logging into the webcast or calling the number below, and instructions will be provided as to how shareholders entitled to vote at the AGM may participate. Please log in a few minutes prior to the start of the meeting.

Virtual AGM Details:

Date: April 7, 2020
Time: 10:00 am EST
Participant Access: 877-407-3088 (toll free number)

Webcast: https://78449.themediaframe.com/dataconf/productusers/fgd/mediaframe/36757/indexl.html

The Company again encourages all shareholders to vote in advance of the meeting and all shareholders may still attend the meeting, while having voted previously by proxy. As noted in the Company's Management Information Proxy Circular, only a shareholder whose own name appears on the records of the Company as a registered holder of common shares can be recognized for the purposes of voting during the meeting. If common shares are listed in an account statement provided to a shareholder by a financial institution or broker, then, in almost all cases, those shares will not be registered in the shareholder's name. Such shares will more likely be registered under the name of the shareholder's financial institution, intermediary, broker or an agent of that broker (their "Nominee"). Shareholders who do not hold shares registered in their own name but wish to vote their shares during the meeting as proxyholder, should contact their Nominee well in advance of the meeting to determine the steps necessary to permit them to do so.

Proxy votes must be submitted by 10:00 AM Eastern on Friday, April 3, 2020. Please refer to the form of proxy regarding voting instructions, including the ability to vote by phone (1-866-732-8683) and online (www.investorvote.com), using the control number provided in your meeting materials. For additional information on the meeting, please refer to the Company's Management Information Proxy Circular.

Corporate Strategy

Our corporate strategy is to grow Fiore Gold into a 150,000 ounce per year gold producer. To achieve this, we intend to:

continue to grow gold production at the Pan Mine, while increasing the resource and reserve base
advance the development of the nearby Gold Rock project
acquire additional production or near-production assets to complement our existing operations

On behalf of FIORE GOLD LTD.

"Tim Warman"
Chief Executive Officer

Contact Us:

info@fioregold.com
1 (416) 639-1426 Ext. 1
www.fioregold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This news release contains "forward-looking statements" and "forward looking information" (as defined under applicable securities laws), based on management's best estimates, assumptions and current expectations. Such statements include but are not limited to, future precautions regarding COVID-19 and their effectiveness, growing gold production at the Pan Mine while increasing the resource and reserve base, advancing exploration and development of the Gold Rock project, goal to become a 150,000-ounce producer, goal to acquire additional production or near production assets, and other statements, estimates or expectations. Often, but not always, these forward-looking statements can be identified by the use of forward-looking terminology such as "expects", "expected", "budgeted", "targets", "forecasts", "intends", "anticipates", "scheduled", "estimates", "aims", "will", "believes", "projects" and similar expressions (including negative variations) which by their nature refer to future events. By their very nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Fiore Gold's control. These statements should not be read as guarantees of future performance or results. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, as well as a number of assumptions made by, and information currently available to, the Company concerning, among other things, anticipated geological formations, potential mineralization, future plans for exploration and/or development, potential future production, ability to obtain permits for future operations, drilling exposure, and exploration budgets and timing of expenditures, all of which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of Fiore Gold to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to vary materially from results anticipated by such forward looking statements include, but not limited to, risks related to the Pan Mine performance, risks related to the company's limited operating history; risks related to international operations; risks related to general economic conditions, actual results of current or future exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates; increases in market prices of mining consumables; possible variations in ore reserves, grade or recovery rates; uncertainties involved in the interpretation of drilling results, test results and the estimation of gold resources and reserves; failure of plant, equipment or processes to operate as anticipated; the possibility that capital and operating costs may be higher than currently estimated; the possibility of cost overruns or unanticipated expenses in the work programs; availability of financing; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of exploration, development or construction activities; the possibility that required permits may not be maintained, obtained or renewed on a timely manner or at all; changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Fiore Gold operates, and other factors identified in Fiore Gold's filing with Canadian securities authorities under its profile at www.sedar.com respecting the risks affecting Fiore Gold and its business. Although Fiore Gold has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements and forward-looking information are made as of the date hereof and are qualified in their entirety by this cautionary statement. Fiore disclaims any obligation to revise or update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments, except as require by law. Accordingly, readers should not place undue reliance on forward-looking statements and information.

SOURCE: Fiore Gold Ltd.

ReleaseID: 582779

Study to Tackle Leading Cause of Death in COVID-19 Patients

Lenzilumab is a monoclonal antibody that neutralizes GM-CSF, a cytokine up-regulated in COVID-19 patients that can cause a harmful immune response leading to acute respiratory distress syndrome (ARDS)
Clinical evidence suggests that this harmful immune response contributes to cytokine storm in COVID-19 patients at risk of developing ARDS
Company plans to study lenzilumab in COVID-19 patients to prevent ARDS and mortality
Company is in a clinical study to prevent cytokine storm in the context of CAR-T cancer therapy with Kite Pharma ("Kite"), a Gilead company

BURLINGAME, CA / ACCESSWIRE / March 27, 2020 / Humanigen, Inc., (OTCQB:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company's proprietary Humaneered® anti-human-granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody, announced that the company has submitted an initial protocol synopsis to the FDA in support of the company's plans to initiate a multi-center, US, Phase III study in COVID-19 patients.

The study, if approved, will be a randomized, controlled, clinical trial with lenzilumab for the prevention and treatment of cytokine storm which can lead to ARDS associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in COVID-19.

"Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results," said Dr. Cameron Durrant, chief executive officer of Humanigen. "We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma. Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study," Durrant concluded.

More details on the company's programs in COVID-19 can be found on the company's website at www.humanigen.com under the COVID-19 tab.

About COVID-19-Induced ARDS

COVID-19 is an infectious disease caused by SARS-CoV-2. COVID-19 has become a global pandemic, with over 460,000 confirmed cases and over 21,000 deaths reported to date. Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS) and death.

ARDS is an acute, life-threatening inflammatory lung injury characterized by hypoxia – a lack of oxygen to the tissue – and stiff lungs due to increased pulmonary vascular permeability. ARDS necessitates hospitalization and mechanical ventilation. A rapid increase in patients with ARDS presents a major challenge for the global public health system given limited hospital beds and ventilators. When implementing standard of care, including mechanical ventilation, ARDS has an overall mortality rate of greater than 40%.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. For more information, visit www.humanigen.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for a Phase III study and the future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe coronavirus infections or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Black Horse Capital and its affiliates owning more than 50% of our outstanding common stock, including their ability to control the company; our lack of profitability and need for additional capital to conduct the Phase III study and operate our business as a going concern; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Investors and media:
ir@humanigen.com

SOURCE: Humanigen, Inc. 

ReleaseID: 582795

CORAL GABLES, FL / ACCESSWIRE / March 27, 2020 / Professional Holding Corp. (NASDAQ:PFHD) and Marquis Bancorp, Inc. of Coral Gables today announced the completion of their merger, effective as of March 26, 2020. The merger agreement was previously announced in August 2019 and has since been approved by the shareholders of both companies and by the regulators.

Following the merger, Marquis Bancorp's subsidiary, Marquis Bank, merged with and into Professional Holding Corp.'s subsidiary, Professional Bank, with Professional Bank continuing as the surviving bank. Based on financials as of December 31, 2019, the combined banking institution has approximately $1.7 billion in assets, making it the 12th largest community bank in Florida and the 4th largest in South Florida.

With the merger, Professional Bank will service 10 South Florida markets and remain headquartered in Coral Gables, Florida. Marquis Bank was established in 2007 and had operated branches in Coral Gables, Aventura and Fort Lauderdale.

"I welcome the Marquis team and their clients to the Professional Bank family," said Professional Bank Chairman & CEO Daniel R. Sheehan who is also Chairman & CEO of Professional Holding Corp. "In the coming months, they will be introduced to the Professional Bank platform that includes robust digital and mobile service offerings, with the integration of both institutions already underway."

Under the terms of the merger agreement, at the effective time of the merger, each share of Marquis Bancorp common stock that was outstanding as of immediately prior to the effective time, other than certain shares held by Marquis Bancorp or Professional Holding Corp., was converted into the right to receive 1.2048 shares of Professional Holding Corp. Class A common stock.

No fractional shares of Professional Holding Corp. Class A common stock were issued. Marquis shareholders became entitled to receive cash in lieu of fractional shares. Each share of Professional Holding Corp. Class A common stock that was outstanding as of immediately prior to the effective time remained outstanding and was unaffected by the merger.

Professional Holding Corp. completed its initial public offering and began trading Feb. 7 on the Nasdaq Global Select Market under the symbol "PFHD". The company raised $59.7 million from its IPO to support continued organic growth and potential future acquisitions.

"The merger's completion is good for our shareholders, employees and clients," said Javier J. Holtz, Marquis Bank's Chairman and CEO. "The combined resources and people of the two banks benefit everyone."

Wachtell, Lipton, Rosen & Katz served as legal advisor to Professional Bank, while Smith MacKinnon, PA served as legal advisor for Marquis Bank. Stephens Inc. served as financial advisor to Professional Bank, while Hovde Group served as financial advisor for Marquis Bank.

###

About Professional Holding Corp. and Professional Bank:

Professional Holding Corp. (NASDAQ: PFHD), is the financial holding company for Professional Bank, a Florida state-chartered bank established in 2008. Professional Bank focuses on providing creative, relationship-driven commercial banking products and services designed to meet the needs of small to medium-sized businesses, the owners and operators of these businesses, other professional entrepreneurs and high net worth individuals. Professional Bank currently operates through a network of five banking centers and four loan production offices in the Miami Metropolitan Statistical Area, as well as its Digital Innovation Center located in Cleveland, Ohio. For more information, visit www.myprobank.com.

Media contacts:

Todd Templin or Eric Kalis, BoardroomPR
ttemplin@boardroompr.com/ekalis@boardroompr.com
954-290-0810

SOURCE: Professional Holding Corp.

ReleaseID: 582822

DALLAS, TX / ACCESSWIRE / March 27, 2020 / The full report can be accessed by clicking on the following link: http://www.stonegateinc.com/reports/BU.TO%20Initiation .pdf

COMPANY DESCRIPTION

Burcon Nutrascience Corporation (TSX:BU) is a leader in the development of plant-based proteins. The Company has developed novel protein ingredients from pea, canola, and soy for use in products such as dairy alternatives, dry-blended beverages, meat substitutes, protein bars and crisps, and ready-to-drink beverages. Headquartered in Vancouver, Canada, the Company was founded in 1998 as a venture capital pool corporation and changed its name to Burcon Nutrascience in October 1999

SUMMARY

Plant Based Foods are Surging – Plant based proteins are in the early innings of adoption with Markets and Markets estimating the plant-based protein market accounted for a value of $18.5 billion in 2019 and will grow at a 14.0% CAGR until 2025 to reach $40.6 billion.
History of Developing Plant Proteins – Burcon NutraScience has spent 20 years and raised ~$80 million in order to perfect and patent their process to extract plant proteins that can be used in the commercial production of foods and beverages.
Partnered With Notable Players – The Company has already partnered with Archer-Daniels-Midland, ADM, in the form of a licensing deal for their soy protein, CLARISOY®, in 2011. ADM built a dedicated plant and launched several CLARISOY® products that have since struggled to gain traction due to stigma and emergence of additional plant proteins such as pea and canola. Additionally, Burcon's JV, Merit Functional Foods, recently announced a partnership with Nestlé to tailor their pea and canola proteins for use in products produced by Nestlé.
Move to Pea and Canola Proteins – Burcon has entered into a JV with three industry veterans to construct a production facility focused on pea and canola proteins with estimated production beginning Q4 2020. Burcon will own 40% of Merit Foods and the facility which will initially produce 4,000 tonnes with ability to grow to 8,000 tonnes in the same facility.
Proteins with Differentiators – Burcon's pea and canola proteins will offer traditional nutritional value as well as functional values such as binding, gelling, whipping/foaming, and emulsification that should enhance the overall benefits to food and beverage producers and consumers.
Experienced Management Team – The Company has a solid balance sheet with ~$18.5 million in cash after receiving ~$11.5 million in financing February. The Company has enough cash to last until September 2022, when we anticipate the Company will be generating positive cash flows.
Burcon Looking Forward- The Company has numerous near term catalysts including production commencing at the 88,00 sq. ft. production facility, product development updates with Nestlé, enhanced production capacity at the production facility, continued R&D for additional alternative plant based protein sources.
Valuation – We believe that TSX:BU offers a unique investment opportunity for the marketplace. Using our DCF framework we have arrived at a valuation range of $1.01 to $2.42 with a mid-point at $1.42

About Stonegate Capital Partners

Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.

CONTACT:
214-987-4121
Shane Martin, CFA

SOURCE: Stonegate Capital Partners

ReleaseID: 582760

HONG KONG / ACCESSWIRE / March 27, 2020 / Established in 2014 as a start-up technology company, DigitalPay Limited is soon to launch its revolutionary money transfer mobile app technology, which has been developed using the latest blockchain technology, for financial institutions across Asia.

With a release date set for early 2022, DigitalPay Limited believe their revolutionary blockchain-based mobile app technology will offer its clients users a faster transaction speed, on a more secure data network and with a 60% lower charge per transaction than their industry competitors.

"Our company has already formed partnerships with many of the biggest financial institutions in Asia, with the app prototype having been implemented and tested on their internal data networks with formidable results so far. We are releasing money transfer app technology for both iOS and Android platforms like no other on the current market", commented Joseph Yong, Head of Investor Relations at DigitalPay Limited.

Since the 2008 economic recession, the financial industry has been faced with a number of challenges concerning trust, reliability and value. The traditional banking transfer process has now been deemed outdated, overpriced and unreliable. Financial institutions are currently looking for an alternative option for their money transfer needs.

DigitalPay insiders believe they will lead the way for next-generation money transfer payments, changing the way payments are conducted and fulfilled by using revolutionary distributed ledger technology (DLT).

"By adopting certain aspects of DLT, DigitalPay have been able to tailor a money transfer solution to better suit our partnering financial institutions. The financial institutions we have partnered with are now equipped to efficiently exchange important information including receiver, sender, fees and foreign exchange info all in real-time, across the globe, with the highest security data environment available and a huge cost saving for their users on each transaction." Commented Liu Hongwei, the company's Chief Technology Officer at DigitalPay Limited.

A 2019 report by the Migration Data Portal shows that China alone is projected to be one of the top money transfer recipient countries in the world, with US$66.8 billion expected to be sent back home by Chinese living abroad.

With revolutionary blockchain technology being used for their soon to be released money transfer technology, DigitalPay Limited are looking to become a market-leader in the booming Asian money transfer-tech industry.

Media contact

DigitalPay Limited
Joseph Yong
+852 5803 1800
www.idigipay.com

SOURCE: DigitalPay Limited

ReleaseID: 582820

NEW YORK, NY / ACCESSWIRE / March 27, 2020 / Wuxi Biologics (Cayman), Inc. (OTCMKTS:WXIBF) will be discussing their earnings results in their 2019 Second Half Earnings call to be held on March 27, 2020 at 9:00 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/60876

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company's profile.

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

ReleaseID: 582799

VANCOUVER, BC / ACCESSWIRE / March 27, 2020 / Evrim Resources Corp. (TSX.V:EVM) ("Evrim" or the "Company") announces that it has terminated the option agreement with Harvest Gold Corporation ("Harvest Gold") on the Cerro Cascaron project in southwestern Chihuahua, Mexico. Evrim and Harvest Gold Corporation ("Harvest Gold") completed two seasons of exploration and ten diamond drill holes at Cerro Cascaron. Drilling results (see Evrim news release dated March 19, 2019) included 20.10 grams per tonne ("g/t") gold and 22.5 g/t silver over one metre in drill hole SPT18-01 at the Serpiente Dorada prospect, and 5.39 g/t gold and 23.7 g/t silver over 0.35 metres in SPED19-02 at the San Pedro prospect. These results and extensive areas of gold-silver showings at lower elevations have not been followed up or tested by drilling.

Evrim thanks Harvest Gold for their contribution to the Cerro Cascaron project and is seeking a new partner to continue the exploration program.

Dave Groves, Evrim's VP of Exploration notes, "Cerro Cascaron is a large concession with extensive epithermal vein and breccia development along arc normal structures in the high country of the Sierra Madre Occidental. Much of the vein field, which is developed over some 900 metres of elevation, remains unexplored, including virtually all of the andesitic Lower Volcanic Sequence (LVS) mapped at lower elevations along seven kilometres of gold-bearing structures."

About the Cerro Cascaron Project

Cerro Cascaron is located 55 kilometres southeast of Goldcorp Inc.'s past-producing El Sauzal gold mine in the Sierra Madre Occidental in Chihuahua state, Mexico (Figure 1). The project covers 69 square kilometres of ground and includes a high-grade gold-silver epithermal vein field spanning approximately 18 square kilometres in the eastern third of the property (Figure 2). Gold-bearing veins, quartz-annealed breccia and silicification of porous tuffaceous units have been mapped and sampled along two major northeast-striking trends and over some 900 vertical metres.

Channel sampling and mapping completed by Evrim in 2016 outlined several areas of high-grade gold veins within the 18 square kilometre vein field at Cerro Cascaron. Surface exploration results included:

Up to 39 g/t gold in chip-channel samples of quartz-tourmaline veins and breccia at La Prieta
Mapping and sampling of a 900 by 350 metre area of gold-silver-bearing quartz veins and breccia in andesite at Divisadero
Identification of a 1.6 kilometre long gold-in-soil anomaly extending north and east of the Julieta and Serpiente Dorada veins
Soil sampling and mapping of new veins (El Salto and La Puerta) within the Cascaron vein field

Figure 1: Cerro Cascaron Location Map, Chihuahua Mexico

Two areas within the Upper Volcanic Sequence (UVS) were tested during an initial round of drilling in late 2018 and early 2019. One hole at Serpiente Dorada intersected 20.1 g/t gold and 22.5 g/t silver over one metre in silicified rhyolitic tuff with sheeted quartz veinlets. The hole was drilled from the top of the rhyolite plateau and failed to reach a zone of coarse visible gold in steeply west-dipping fractures sampled below the cliff face. Another hole, SPED19-02 drilled oblique to the San Pedro vein intersected 5.4 g/t gold and 23.7 g/t silver over 0.35 metres. Three holes drilled at the Cascarita silver target on the western of the property and did not return significant results.

Mapping and sampling to date have been focused on the vein fields in the Upper Volcanic Sequence (UVS) at higher elevations, including the Serpiente Dorada, San Pedro, Julieta and Carabina veins. Gold-in-soil anomalies and pathfinder anomalies (Hg, Sb, Tl) outline these vein systems to the northeast for more than two kilometres. To the southwest, ore-controlling structures can be traced an additional two kilometres through the La Reyna, Santa Rita and Divisidero workings in the Lower Volcanic Sequence (LVS).

Additional drilling is warranted at Serpiente Dorada and La Julieta given initial results. The Lower Volcanic Sequence (LVS) also requires soil coverage and additional mapping to better outline untested extensions to productive structures.

Figure 2: Extent of the Cerro Cascaron vein field through Lower and Upper Sequence rocks

Qualified Person Statement

Evrim's disclosure of technical and scientific information in this news release has been reviewed by Dave Groves, Vice President, Exploration for Evrim. Mr. Groves is a Certified Professional Geologist (#11456) with the American Institute of Professional Geologists and a Qualified Person under the definition of National Instrument 43-101.

About Evrim Resources

Evrim Resources is a mineral exploration company whose goal is to participate in significant exploration discoveries supported by a sustainable business model. The Company is well financed, has a diverse range of quality projects and a database covering substantial areas of Mexico and portions of southwestern United States. The Company's projects are advanced through option and joint venture agreements with industry partners to create shareholder value. Evrim's business plan also includes royalty creation utilizing the Company's exploration expertise and existing projects.

On Behalf of the Board

EVRIM RESOURCES CORP.

Paddy Nicol

President & CEO

To find out more about Evrim Resources Corp., please contact Paddy Nicol, President, Dave Groves, VP of Exploration at daveg@evrimresources.com, or Liliana Wong, Manager, Marketing & Investor Relations at 604-425-3400.

Visit our website at www.evrimresources.com.

1201-510 WEST HASTINGS ST. VANCOUVER, BC, CANADA V6B 1L8
TEL: 604.248.8648
FAX: 604.248.8663
WWW.EVRIMRESOURCES.COM

Forward Looking Information

This news release includes certain statements that may be deemed "forward looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that Evrim Resources Corp. (the "Company") expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

SOURCE: Evrim Resources Corp.

ReleaseID: 582720